Evaluation of Melatonin efficacy in prophylaxis of Doxorubicin induced cardiotoxicity in patients with breast cancer and receiving the Doxorubicin-Cyclophosphamide regimen : Double-blind randomized clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 56 人开始时间: 待定最近更新: 2022年1月11日

适应症

试验速览

暂无简介。

•People who have recently been definitively diagnosed with breast cancer and are candidates for a chemotherapy regimen containing doxorubicin
•Having the consent to participate in the study
•Age over 18 years
•Ability to consume orally
•Normal liver function (serum bilirubin less than 1.5 mg / dl)
•No CKD or SrCreatinine> 2 mg / dL or eGFR <30 mL / min / m2

•Patients with a history of breast cancer or a history of chemotherapy drugs that cause cardiotoxicity
•Patients who are unable to receive doxorubicin for any reason
•Patient with LVEF <50% before starting treatment
•Use of ACE inhibitors, ARBs, beta-blockers or in the treatment of heart failure
•Having coronary or valvular heart disease, cardiomyopathy, hypertension or AF
•History of receiving chest radiotherapy
•Patients with neurological injuries such as Parkinson's, stroke, seizures, etc.
•Those who are taking an antioxidant drug such as vitamin E, NAC, etc.
•Participate in other clinical studies simultaneously
•Known sensitivity to any of the consumables in the study

发起方